Libros sobre el tema "Monoamides"

Binda, Claudia, ed. Monoamine Oxidase. New York, NY: Springer US, 2023. http://dx.doi.org/10.1007/978-1-0716-2643-6.

Oreland, Lars y Brian A. Callingham, eds. Monoamine Oxidase Enzymes. Vienna: Springer Vienna, 1987. http://dx.doi.org/10.1007/978-3-7091-8901-6.

National Institutes of Health (U.S.), ed. Low monoamine (LMA) diet. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1989.

Szelenyi, I., ed. Inhibitors of Monoamine Oxidase B. Basel: Birkhäuser Basel, 1993. http://dx.doi.org/10.1007/978-3-0348-6348-3.

Roberts, M. H. T. The central and antinociceptive actions of the monoamines. Birmingham: University of Birmingham, 1986.

H, Yasuhara, ed. Monoamine oxidase: Basic and clinical aspects. Utrecht, Netherlands: VSP, 1993.

Van Bockstaele, Elisabeth J., ed. Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7940-6.

H, Kennedy Sidney, ed. Clinical advances in monoamine oxidase inhibitor therapies. Washington, DC: American Psychiatric Press, 1994.

Ebrahimi, Soltan Ahmed. Characterisation of guinea pig liver monoamine oxidase. Portsmouth: University of Portsmouth, School of Pharmacy and Biomedical Science, 1995.

G, Priest R., ed. Depression and reversible monoamine oxidase inhibitors: New perspectives. London: Royal College of Psychiatrists, 1989.

Michel, Bourin, ed. Les IMAO. Paris: Ellipses-Marketing, 1993.

Yu, Qinghui. Developmental Monoamine Signaling Impacts Adult Affective and Aggressive Behaviors. [New York, N.Y.?]: [publisher not identified], 2012.

Next generation antidepressants: Moving beyond monoamines to discover novel treatment strategies for mood disorders. Cambridge: Cambridge University Press, 2010.

D, Burrows Graham y Da Prada M, eds. Reversible MAO-A inhibitors as antidepressants: Basic advances and clinical perspectives. Wien: Springer-Verlag, 1989.

M, Yu Peter, Boulton A. A y Tipton Keith F, eds. Current neurochemical and pharmacological aspects of biogenic amines: Their function, oxidative deamination, and inhibition. Amsterdam: Elsevier, 1995.

M, Yu Peter, Boulton A. A y Tipton Keith F, eds. Current neurochemical and pharmacological aspects of biogenic amines: Their function, oxidative deamination, and inhibition. Amsterdam: Elsevier, 1995.

1941-, Szelenyi I., ed. Inhibitors of monoamine oxidase B: Pharmacology and clinical use in neurodegenerative disorders. Basel: Birkhäuser, 1993.

F, Tipton Keith, ed. Amine oxidases: Function and dysfunction : proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22-25, 1992. Wien: Springer-Verlag, 1994.

Biogenic monoamines and their metabolites in the urine, plasma, and cerebrospinal fluid of normal, psychiatric, and neurological subjects. Boca Raton, Fla: CRC Press, 1990.

National Institutes of Health (U.S.), ed. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), ed. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), ed. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), ed. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), ed. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

National Institutes of Health (U.S.), ed. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, National Institutes of Health, 1989.

Yu, Wai Haung. Desferrioxamine analysis by high performance liquid chromatography, stability and metabolic inhibition by monoamine oxidase inhibitors. Ottawa: National Library of Canada, 1994.

Zeric, Tamara. Peri-adolescent monoamine interference alters behavioral response to cocaine and associated dopamine dynamics in adulthood. [New York, N.Y.?]: [publisher not identified], 2022.

Karpowicz, Richard. I. Advanced Fluorescent False Neurotransmitters for the Study of Monoamine Transporter Activity and Synaptic Transmission. [New York, N.Y.?]: [publisher not identified], 2013.

Umberto, Di Porzio, Pernas-Alonso Roberto y Perrone-Capano Carla, eds. Development of dopaminergic neurons. Austin: R.G. Landes Co., 1999.

IBRO International Symposium on Neuroendocrinology (1985 Leningrad, R.S.F.S.R.). IBRO International Symposium on Neuroendocrinology: "Peptide and monoamine neurohormones in neuroendocrine regulation", Leningrad, August 19--23, 1985 : abstracts. Editado por Polenov Andreĭ Lʹvovich, Akademii͡a︡ nauk SSSR, International Brain Research Organization. Soviet National Committee. y Institut ėvoli͡u︡t͡s︡ionnoĭ fiziologii i biokhimii im. I.M. Sechenova. Leningrad: [s.n.], 1985.

Rúzsás, Csilla. Maturation and aging of neuroendocrine functions: The role of monoaminergic neurons and of the pineal gland. Budapest: Akadémiai Kiadó, 2001.

Praag, Herman M. van 1929-, Plutchik Robert y Apter Alan, eds. Violence and suicidality: Perspectives in clinical and psychobiological research. New York: Brunner/Mazel, 1990.

Torre, J. de la. Dynamics of Brain Monoamines. Springer, 2012.

Torre, J. de la. Dynamics of Brain Monoamines. Springer, 2012.

Torre, J. de la. Dynamics of Brain Monoamines. Springer London, Limited, 2012.

Isocyclische Monoamine. 4^a ed. Springer, 2029.

Roze, Emmanuel y Nenad Blau. Biogenic Monoamine Disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199972135.003.0031.

Low monoamine (LMA) diet. [Bethesda, Md.?: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1988.

John P.M. Finberg (Editor), Moussa B.H. Youdim (Editor), Peter Riederer (Editor) y K. F. Tipton (Editor), eds. MAO-The Mother of All Amine Oxidases (Journal of Neural Transmission Supplementa). Springer, 2003.

Monoamine Oxidase and their Inhibitors. Elsevier, 2011. http://dx.doi.org/10.1016/c2009-0-01862-5.

Monoamine Oxidase and Its Inhibition. Wiley & Sons, Incorporated, John, 2009.

Riederer, Peter y Moussa Youdim. Monoamine Oxidases and Their Inhibitors. Elsevier Science & Technology Books, 2011.

Binda, Claudia. Monoamine Oxidase: Methods and Protocols. Springer, 2022.

Knight, Julie y G. E. W. Wolstenholme. Monoamine Oxidase and Its Inhibition. Wiley & Sons, Limited, John, 2008.

Riederer, Peter y Moussa Youdim. Monoamine Oxidases and Their Inhibitors. Elsevier Science & Technology Books, 2011.

Jes, Olesen y Edvinsson Lars, eds. Headache pathogenesis: Monoamines, neuropeptides, purines, and nitric oxide. Philadelphia: Lippincott-Raven, 1997.

Tipton, K. F., M. B. H. Youdim y C. J. Barwell. Amine Oxidases: Function and Dysfunction : Proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22-25, 1992 (Journal of Neural Transmission Supplementum). Springer-Verlag Telos, 1994.

1938-, Lieberman A. N., ed. Monoamine oxidase inhibitors in neurological diseases. New York: M. Dekker, 1994.

1939-, Oreland L., Callingham B. A y Workshop on Amine Oxidases (2nd : 1986 : Biomedical Center, Uppsala University), eds. Monoamine oxidase enzymes: Review and overview. Wien: Springer-Verlag, 1987.

Nagatsu, Hasan Parvez y Yasuhara. Monoamine Oxidase: Basic and Clinical Aspects. Taylor & Francis Group, 1993.